Vascular Dementia Clinical Trial
Official title:
Trial of Remote Ischemic Pre-Conditioning in Vascular Cognitive Impairment
Cerebral small vessel disease is a common cause of cognitive impairment. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion and increase cerebral blood flow. Patients with cognitive impairment, preserved basic activities of daily living, and brain computed tomography (CT) or magnetic resonance imaging (MRI) evidence of confluent white matter hyperintensities or multiple brain infarcts will be randomized to either RIC performed once a day on one arm, or twice per day on one arm, for 30 days, to test tolerability and effects on MRI markers of blood flow.
Cerebral small vessel disease (cSVD) accounts for 20-25% of all strokes and is the most common cause of vascular cognitive impairment (VCI) as well as a major contributor to mixed dementia, potentially interacting with Alzheimer's disease. Remote ischemic pre-conditioning (RIC) is a technique to induce brief periods of limb ischemia-reperfusion that is hypothesized to increase tolerance of the brain to hypoperfusion. This is a prospective, open-label randomized controlled clinical trial with blinded endpoint assessment (PROBE). Participants that complete a 14-day run-in period will be randomized to 30 days of either: a) RIC performed once per day on one arm, or b) RIC performed twice per day on one arm. Each RIC session will consist of 4 cycles of unilateral upper arm ischemia for 5 minutes followed by reperfusion for another 5 minutes, administered by modified blood pressure monitor (under an Investigational Trail Authorization from Health Canada). The primary outcome is tolerability, defined as the proportion in each trial arm that complete 80% or more of the assigned RIC sessions. Secondary outcomes will include pain scores, cognition, and MRI markers of cerebral blood flow and white matter integrity. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Not yet recruiting |
NCT06416371 -
Retinal Vessel Leakage in Cerebral Small Vessel Disease
|
||
Completed |
NCT01761227 -
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
|
Phase 2 | |
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT00165763 -
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
|
Phase 4 | |
Completed |
NCT00621647 -
Seroquel- Agitation Associated With Dementia
|
Phase 3 | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Recruiting |
NCT03275363 -
The University of Hong Kong Neurocognitive Disorder Cohort
|
N/A | |
Active, not recruiting |
NCT03804229 -
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
|
Phase 3 | |
Enrolling by invitation |
NCT03724136 -
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
|
N/A | |
Completed |
NCT02453932 -
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
|
Phase 3 | |
Completed |
NCT00947531 -
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
|
Phase 4 | |
Not yet recruiting |
NCT03702543 -
Managing Vascular Dementia Risk Factors With SymTrend
|
Phase 1 | |
Enrolling by invitation |
NCT02147652 -
Personalized Music Therapy and Agitation in Dementia
|
N/A | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|
||
Recruiting |
NCT06034509 -
Cognitive and Vascular Functioning Following TBI
|
||
Recruiting |
NCT05921266 -
Urolithin A Supplementation in Middle-aged Adults With Obesity
|
N/A | |
Completed |
NCT01465360 -
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
|
N/A | |
Not yet recruiting |
NCT01466543 -
Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
|
Phase 2 |